Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine (TMC125) and Rilpivirine (TMC278): Implications for Drug Design.Lansdon, E.B., Brendza, K.M., Hung, M., Wang, R., Mukund, S., Jin, D., Birkus, G., Kutty, N., Liu, X.
(2010) J Med Chem 53: 4295-4299
- PubMed: 20438081
- DOI: https://doi.org/10.1021/jm1002233
- Primary Citation of Related Structures:
3MEC, 3MED, 3MEE, 3MEG
- PubMed Abstract:
Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent flexibility, helping to maintain activity against a wide range of resistance mutations. Crystal structures were determined with wild-type and K103N HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278). These structures reveal a similar binding mode for TMC125 and TMC278, whether bound to wild-type or K103N RT. Comparison to previously published structures reveals differences in binding modes for TMC125 and differences in protein conformation for TMC278.
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, USA. email@example.com